Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Heteroaroyl indazole lrrk2 inhibitors: MerckRecent Research Landscape

Off-target kinase binding and protein aggregation lead to neurodegenerative progression. These specific heterocyclic scaffolds modulate enzyme activity to arrest pathological alpha-synuclein accumulation.

What technical problems is Merck addressing in Heteroaroyl indazole lrrk2 inhibitors?

Neurodegenerative protein kinase dysfunction

(3)evidences

Pathological accumulation of alpha-synuclein and hyperactive LRRK2 signaling drive neuronal cell death. Mitigating these biochemical malfunctions prevents progressive central nervous system degradation.